ES2155849T3 - Azetidinonas sustituidas con espirocicloalquilo, utiles como agentes hipocolesterolemicos. - Google Patents

Azetidinonas sustituidas con espirocicloalquilo, utiles como agentes hipocolesterolemicos.

Info

Publication number
ES2155849T3
ES2155849T3 ES94907200T ES94907200T ES2155849T3 ES 2155849 T3 ES2155849 T3 ES 2155849T3 ES 94907200 T ES94907200 T ES 94907200T ES 94907200 T ES94907200 T ES 94907200T ES 2155849 T3 ES2155849 T3 ES 2155849T3
Authority
ES
Spain
Prior art keywords
always
alkenylene
compounds
sum
optionally
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94907200T
Other languages
English (en)
Inventor
Sundeep Dugar
John W Clader
Duane A Burnett
Margaret E Browne
Harry R Davis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of ES2155849T3 publication Critical patent/ES2155849T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/12—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

NUEVOS COMPUESTOS DE FORMULA (1) O SALES FARMACEUTICAMENTE ACEPTABLES DE LOS MISMOS, EN DONDE R1 ES (A); R2 Y R3 SE SELECCIONAN INDEPENDIENTEMENTE DE UN GRUPO QUE ESTA COMPUESTO POR -CH2-, -CH(ALKIL INFERIOR)-, -C(DI-ALKIL INFERIOR)-, -CH=CH- Y -C(ALKIL INFERIOR)=CH-; O R1 JUNTO CON UN R2 ADYACENTE O R1 JUNTO CON R3 ADYACENTE, FORMAN UN -CH=CH- O UN GRUPO -CH=C (ALKILO INFERIOR); U Y V SON INDEPENDIENTEMENTE 0, 1, 2 O 3, SIEMPRE QUE AMBOS NO SEAN CERO; SIEMPRE QUE CUANDO R2 ES -CH=CH- O -C(ALKILO INFERIOR)=CH-, V ES 1; SIEMPRE QUE CUANDO R3 ES -CH=CH O C(ALKILO INFERIOR)=CH-, U ES 1; SIEMPRE QUE CUANDO V SEA 2 O 3, LOS DE R2 PUEDAN SER IGUALES O DIFERENTES; SIEMPRE QUE CUANDO U ES 2 O 3, LOS DE R3 PUEDAN SER IGUALES O DIFERENTES; R4 ES B(CH2)MC(O), EN DONDE M ES DE 0 A 5; B-(CH2)Q-, EN DONDE Q ES DE 0 A 6; B-(CH2)E-Z-(CH2)E-EN DONDE Z ES -O-, C-(O)-,FENILENO, N(R8)- O -S(O)0-2, E ES DE 0 A 5, SIEMPRE QUE LA SUMA DE E Y R SEA DE 0 A 6; B-(C2-C6 ALKENILENO); B''-(C4-C6 ALKADIENILENO)-;B(CH2)T-Z-(C2-C6 ALKENILENO)-, EN DONDE T ES DE 0 A 3, SIEMPRE QUE LA SUMA DE T Y EL NUMERO DE ATOMOS DE CARBONO EN LA CADENA DEL ALKENILENO SEA DE 2 A 6; B-(CH2)F-V-(CH2)G-, EN DONDE V ES C3-C6 CICLOALKILENO, F ES DE 1 A 5 Y G ES DE 0 A 5, SIEMPRE QUE LA SUMA DE F Y G SEA 1 A 6; B-(CH2)T-V-(C2-C6)ALKENILENO- O B''-(C2-C6 ALKENILENO)-V-(CH2)T- SIEMPRE QUE LA SUMA DE T Y EL NUMERO DE ATOMOS DE CARBONO EN LA CADENA ALKENILENO SEA 2, 3, 4, 5 O 6; B-(CH2)A-Z(CH2)B-V(CH2)D,DONDE A, B Y D SON INDEPENDIENTEMENTE DE 0 A 6, SIEMPRE QUE LA SUMA DE A, B Y D ES DE O A 6; T-(CH2)S-, DONDE T ES CICLOALKIL CON DE 3 A 6 ATOMOS DE CARBON Y S ES DE 0 A 6; O R1 Y R2 FORMAN JUNTOS UN GRUPO(A''); B ES FENILO OPCIONALMENTE SUSTITUIDO, INDANILO, INDENILO NAFTILO, TETRAHIDRONAFTILO U OPCIONALMENTE HETEROARILO SUSTITUIDO; Y R20 Y R21 SON INDEPENDIENTEMENTE FENILO OPCIONALMENTE SUSTITUIDO, NAFTILO OPCIONALMENTE SUSTITUIDO, INDANILO, INDENILO, TETRAHIDRONAFTILO, BENZODIOXOLILO, HETEROARILO OPCIONALMENTE SUSTITUIDO, HETEROARILOBENZOFUNDIDO OPCIONALMENTE SUSTITUIDO O CICLOPROPILO; HAN SIDO DESCUBIERTOS ASI COMO COMPOSICIONES FARMACEUTICAS QUE COMPRENDEN LOS CITADOS COMPUESTOS, EL USO DE LOS CITADOS COMPUESTOS COMO AGENTES HIPOCOLESTEROLEMICOS, LOS PROCESOS PARA LA PREPARACION DE LOS COMPUESTOS Y EL USO DE LOS CITADOS COMPUESTOS EN COMBINACION CON LOS INHIBIDORES DE LA BIOSINTESIS DEL COLESTEROL PARA TRATAR O PREVENIR LA ATEROSCLEROSIS.
ES94907200T 1993-01-21 1994-01-19 Azetidinonas sustituidas con espirocicloalquilo, utiles como agentes hipocolesterolemicos. Expired - Lifetime ES2155849T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US643993A 1993-01-21 1993-01-21

Publications (1)

Publication Number Publication Date
ES2155849T3 true ES2155849T3 (es) 2001-06-01

Family

ID=21720894

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94907200T Expired - Lifetime ES2155849T3 (es) 1993-01-21 1994-01-19 Azetidinonas sustituidas con espirocicloalquilo, utiles como agentes hipocolesterolemicos.

Country Status (26)

Country Link
US (1) US5698548A (es)
EP (1) EP0681569B1 (es)
JP (1) JP2719445B2 (es)
KR (1) KR960700227A (es)
CN (1) CN1118163A (es)
AT (1) ATE199899T1 (es)
AU (1) AU683048B2 (es)
CA (1) CA2154257C (es)
CZ (1) CZ180195A3 (es)
DE (1) DE69426924T2 (es)
DK (1) DK0681569T3 (es)
EE (1) EE9400394A (es)
ES (1) ES2155849T3 (es)
FI (1) FI953497A0 (es)
GR (1) GR3035963T3 (es)
HU (1) HUT72592A (es)
IL (1) IL108368A0 (es)
LT (1) LT3595B (es)
NO (1) NO952884L (es)
NZ (1) NZ261714A (es)
PL (1) PL309978A1 (es)
PT (1) PT681569E (es)
SI (1) SI9400022A (es)
SK (1) SK91195A3 (es)
WO (1) WO1994017038A1 (es)
ZA (1) ZA94386B (es)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0647234A1 (en) * 1992-06-26 1995-04-12 Pfizer Inc. Steroidal glycosides for treating hypercholesterolemia
US5631365A (en) 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
US5656624A (en) * 1994-12-21 1997-08-12 Schering Corporation 4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents
US5648484A (en) * 1995-03-07 1997-07-15 Schering Corporation Catalytic enantioselective synthesis of a spriofused azetidinone
PT877750E (pt) 1995-10-31 2002-09-30 Schering Corp 2-azetidinonas substituidas por acucar uteis como agentes hipocolesterolemiantes
US5756470A (en) * 1996-10-29 1998-05-26 Schering Corporation Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
WO2000063703A1 (en) 1999-04-16 2000-10-26 Schering Corporation Use of azetidinone compounds
US6297268B1 (en) 1999-11-30 2001-10-02 Schering Corporation Imidazoles as cholesterol lowering agents
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
RU2297422C2 (ru) * 2000-12-20 2007-04-20 Шеринг Корпорейшн Замещенные остатком сахара 2-азетидиноны, пригодные для использования в качестве гипохолестеринемических препаратов
AU2005246926B2 (en) * 2001-01-26 2008-02-28 Merck Sharp & Dohme Corp. The use of substituted azetidinone compounds for the treatment of sitosterolemia
IL156445A0 (en) 2001-01-26 2004-01-04 Schering Corp Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
EP1911462A3 (en) 2001-01-26 2011-11-30 Schering Corporation Compositions comprising a sterol absorption inhibitor
SK9502003A3 (en) * 2001-01-26 2003-12-02 Schering Corp Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
AR035533A1 (es) 2001-01-26 2004-06-02 Schering Corp Uso de por lo menos un inhibidor de la absorcion de los esteroles o sus sales, solvatos, prodrogas farmaceuticamente aceptables o mezclas de los mismos para la preparacion de un medicamento para el tratamiento de la sitosterolemia, composiciones farmaceuticas, el uso de dichas composiciones para la
EE05453B1 (et) 2001-03-28 2011-08-15 Schering Corporation Protsess asetidinoonvahehendite valmistamiseks
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
MXPA04002573A (es) 2001-09-21 2004-06-18 Schering Corp Tratamiento de xantoma con derivados de azetidinona como inhibidores de la absorcion de esterol.
EP1859796A3 (en) * 2001-09-21 2008-07-02 Schering Corporation Treatment of xanthoma with azetidinone derivatives as sterol absorption inhibitors
US20030204096A1 (en) * 2002-03-25 2003-10-30 Schering Corporation Enantioselective synthesis of azetidinone intermediate compounds
GB0215579D0 (en) 2002-07-05 2002-08-14 Astrazeneca Ab Chemical compounds
US20040132058A1 (en) 2002-07-19 2004-07-08 Schering Corporation NPC1L1 (NPC3) and methods of use thereof
US7135556B2 (en) * 2002-07-19 2006-11-14 Schering Corporation NPC1L1 (NPC3) and methods of use thereof
AR040588A1 (es) * 2002-07-26 2005-04-13 Schering Corp Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
US6933292B2 (en) * 2002-07-30 2005-08-23 Children's Medical Center Corporation Compositions of ezetimibe and methods for the treatment of cholesterol-associated benign and malignant tumors
WO2004043457A1 (en) 2002-11-06 2004-05-27 Schering Corporation Cholesterol absorptions inhibitors for the treatment of autoimmune disorders
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
JP2006519869A (ja) 2003-03-07 2006-08-31 シェーリング　コーポレイション 置換アゼチジノン化合物、置換アゼチジノン化合物を調製するためのプロセス、それらの処方物および使用
CA2517572C (en) 2003-03-07 2011-12-13 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
EP1601668B1 (en) 2003-03-07 2008-08-27 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
NZ543102A (en) 2003-04-24 2008-12-24 Incyte Corp Aza spiro alkane derivatives as inhibitors of metalloproteases
JP2005015434A (ja) * 2003-06-27 2005-01-20 Kotobuki Seiyaku Kk 血清コレステロール低下剤或はアテローム性硬化症の予防又は治療剤
EP1918000A2 (en) 2003-11-05 2008-05-07 Schering Corporation Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions
JP2007510659A (ja) * 2003-11-05 2007-04-26 シェーリング　コーポレイション 脂質調節剤および置換アゼチジノンの組み合わせならびに血管状態の処置
EP1699759B1 (en) 2003-12-23 2010-10-20 AstraZeneca AB Diphenylazetidinone derivates possessing cholesterol absorption inhibitory activity
CN100471835C (zh) * 2003-12-23 2009-03-25 默克公司 抗高胆固醇血症化合物
WO2005069900A2 (en) * 2004-01-16 2005-08-04 Merck & Co., Inc. Npc1l1 (npc3) and methods of identifying ligands thereof
EP1598336A1 (en) * 2004-05-20 2005-11-23 Laboratorios Del Dr. Esteve, S.A. Regioselective hydroxylation, functionalisation and protection of spirolactams
US7291728B2 (en) 2004-05-10 2007-11-06 Laboratories Del Dr. Esteve, S.A. Spirolactams and their synthesis
EP1676836A1 (en) * 2004-12-30 2006-07-05 Laboratorios Del Dr. Esteve, S.A. Regioselective hydroxylation, functionalisation and protection of spirolactams II
US20080045726A1 (en) * 2004-05-10 2008-02-21 Laboratorios Del Dr. Esteve, S.A. Spirolactams and Their Synthesis
JP2007536329A (ja) * 2004-05-10 2007-12-13 ラボラトリオス・デル・ドクトル・エステベ・ソシエダッド・アノニマ スピロラクタム類の位置選択的官能化および保護
WO2006039334A1 (en) * 2004-09-29 2006-04-13 Schering Corporation Combinations of substituted azetidonones and cb1 antagonists
CN101115726A (zh) 2004-12-03 2008-01-30 先灵公司 作为cb1拮抗剂的取代哌嗪
US8361999B2 (en) 2005-04-04 2013-01-29 Pontificia Universidad Catolica De Chile Methods of treating cholesterol gallstone disease with ezetimibe
DE602006010870D1 (de) * 2005-06-20 2010-01-14 Schering Corp Als antagonisten von histamin h3 geeignete piperidinderivate
SA06270191B1 (ar) 2005-06-22 2010-03-29 استرازينيكا ايه بي مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم
MX2008008340A (es) * 2005-12-21 2008-09-03 Schering Corp Tratamiento de enfermedad de higado graso no alcoholica usando agentes reductores de colesterol y/o antagonista/agonista inverso de receptor de histamina 3.
AR059021A1 (es) 2006-01-18 2008-03-05 Schering Corp Moduladores de receptores cannabinoides
EP1986489A2 (en) 2006-02-24 2008-11-05 Schering Corporation Npc1l1 orthologues
TW200811098A (en) 2006-04-27 2008-03-01 Astrazeneca Ab Chemical compounds
WO2008030382A1 (en) * 2006-09-05 2008-03-13 Schering Corporation Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis
CN101534818A (zh) * 2006-09-15 2009-09-16 先灵公司 用于治疗疼痛和脂类代谢疾病的氮杂环丁烷和氮杂环丁酮衍生物
AR062790A1 (es) 2006-09-15 2008-12-03 Schering Corp Derivados de azetidina utiles en el tratamiento del dolor, diabetes y trastornos del metabolismo de los lipidos
CN101528227A (zh) * 2006-09-15 2009-09-09 先灵公司 氮杂环丁酮衍生物及其使用方法
WO2008033464A2 (en) * 2006-09-15 2008-03-20 Schering Corporation Azetidinone derivatives for the treatment of disorders of the lipid metabolism
AU2007294763A1 (en) * 2006-09-15 2008-03-20 Schering Corporation Treating pain, diabetes, and lipid metabolism disorders
US20080070890A1 (en) * 2006-09-15 2008-03-20 Burnett Duane A Spirocyclic Azetidinone Compounds and Methods of Use Thereof
CN101541805A (zh) 2006-09-15 2009-09-23 先灵公司 用于治疗疼痛和脂代射紊乱的氮杂环丁烷和氮杂环丁酮衍生物
US20100197564A1 (en) * 2007-04-19 2010-08-05 Schering Corporation Diaryl morpholines as cb1 modulators
US8623873B2 (en) 2007-06-28 2014-01-07 Intervet Inc. Substituted piperazines as CB1 antagonists
US20100286160A1 (en) * 2007-06-28 2010-11-11 Intervet Inc. Substituted piperazines as cb1 antagonists
CA2754384A1 (en) 2009-03-06 2010-09-10 Lipideon Biotechnology Ag Pharmaceutical hypocholesterolemic compositions
CN101993403B (zh) 2009-08-11 2012-07-11 浙江海正药业股份有限公司 氮杂环丁酮类化合物及医药应用
CA2792234C (en) 2010-03-19 2014-05-27 Pfizer Inc. 2,3 dihydro-1h-inden-1-yl-2,7-diazaspiro [3.5] nonane derivatives and their use as antagonists or inverse agonists of the ghrelin receptor
MX365046B (es) 2012-05-01 2019-05-17 Althera Life Sciencies Llc Formulacion de tableta oral que consiste de una combinacion fija de rosuvastatina y ezetimiba para el tratamiento de hiperlipidemia y enfermedades cardiovasculares.
CN104496839B (zh) * 2014-12-03 2016-04-20 广东东阳光药业有限公司 取代环丁烷类神经氨酸酶抑制剂及其使用方法和用途
CN104496838B (zh) * 2014-12-03 2016-04-20 广东东阳光药业有限公司 取代环丁烷类神经氨酸酶抑制剂及其使用方法和用途
US11401273B2 (en) 2018-11-20 2022-08-02 Piramal Pharma Limited Asymmetric synthesis of Azaspiro compounds
WO2020191163A1 (en) 2019-03-20 2020-09-24 Regeneron Pharmaceuticals, Inc. Treatment of increased lipid levels with sterol regulatory element binding protein cleavage-activating protein (scap) inhibitors
JP7574206B2 (ja) 2019-03-20 2024-10-28 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ステロール調節エレメント結合転写因子１（ｓｒｅｂｆ１）阻害剤による上昇した脂質レベルの治療
US20250059187A1 (en) * 2021-12-22 2025-02-20 The Regents Of The University Of California Covalently binding inhibitors of g12s, g12d and/or g12e mutants of k-ras gtpase
AU2024335101A1 (en) 2023-08-29 2026-02-26 Regeneron Pharmaceuticals, Inc. Treatment of muscle disorder with folliculin interacting protein 1 (fnip1) inhibitors and/or folliculin (flcn) inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2048080C3 (de) * 1970-09-30 1979-11-29 Basf Ag, 6700 Ludwigshafen Verfahren zur Herstellung von N-substituierten 33-disubstituierten ß -Lactamen
US4692515A (en) * 1984-09-24 1987-09-08 Pennwalt Corporation Adamantane-spirolactams
IL89835A0 (en) 1988-04-11 1989-12-15 Merck & Co Inc Substituted azetidinones,their preparation and pharmaceutical compositions containing them
US4983597A (en) 1989-08-31 1991-01-08 Merck & Co., Inc. Beta-lactams as anticholesterolemic agents
US5130425A (en) * 1990-10-12 1992-07-14 American Home Products Corporation Spiro-lactams and analogs thereof useful as aldose reductase inhibitors
ES2107548T3 (es) * 1991-07-23 1997-12-01 Schering Corp Compuestos de beta-lactama sustituidos utiles como agentes hipocolesterolemicos y procedimientos para su preparacion.

Also Published As

Publication number Publication date
EE9400394A (et) 1996-06-17
EP0681569B1 (en) 2001-03-21
FI953497A7 (fi) 1995-07-20
HU9502194D0 (en) 1995-09-28
JP2719445B2 (ja) 1998-02-25
LT3595B (en) 1995-12-27
CN1118163A (zh) 1996-03-06
FI953497A0 (fi) 1995-07-20
AU683048B2 (en) 1997-10-30
NO952884D0 (no) 1995-07-20
HUT72592A (en) 1996-05-28
LTIP1764A (en) 1995-02-27
CZ180195A3 (en) 1996-01-17
SI9400022A (en) 1995-02-28
ZA94386B (en) 1994-07-19
KR960700227A (ko) 1996-01-19
EP0681569A1 (en) 1995-11-15
DE69426924T2 (de) 2001-08-16
JPH08501110A (ja) 1996-02-06
IL108368A0 (en) 1994-04-12
ATE199899T1 (de) 2001-04-15
CA2154257C (en) 1999-05-25
GR3035963T3 (en) 2001-08-31
NZ261714A (en) 1997-02-24
DE69426924D1 (de) 2001-04-26
SK91195A3 (en) 1995-12-06
PT681569E (pt) 2001-06-29
US5698548A (en) 1997-12-16
AU6087294A (en) 1994-08-15
NO952884L (no) 1995-09-20
WO1994017038A1 (en) 1994-08-04
CA2154257A1 (en) 1994-08-04
DK0681569T3 (da) 2001-04-23
PL309978A1 (en) 1995-11-13

Similar Documents

Publication Publication Date Title
ES2155849T3 (es) Azetidinonas sustituidas con espirocicloalquilo, utiles como agentes hipocolesterolemicos.
CY1273A (en) 1-(dihydroxyphenyl)-2-amino-ethanol derivatives;preparation,compositions and intermediates
ES8105299A1 (es) Procedimiento para preparar aroilimidazol-2-onas
KR950000676A (ko) 신규 설포닐아미노 피리미딘
MY102908A (en) Isoxazole and furan derivatives, their preparation and use as antiviral agents.
FI915970A0 (fi) Laekemedel, som aer nyttiga vid vaord av cancer och som har antihistaminegenskaper.
KR960702820A (ko) 방향족 아세틸콜린에스테라제 억제제 (Aromatic acetylcholinesterase inhibitors)
GB8501192D0 (en) Therapeutic agents
EP0765865A4 (en) 2-ACYLAMINOPROPANOL COMPOUND AND MEDICINAL COMPOSITION
ES8106499A1 (es) Un procedimiento para la preparacion de nuevos derivados de 4-(3-fenilpropil)piperidina
FI961507A0 (fi) Antrasyklinonijohdannaiset ja niiden käyttö amyloidoosissa
ES2163715T3 (es) Compuestos y composiciones de naftilo.
ES2086528T3 (es) Nuevos compuestos biciclicos sustituidos con amino.
MX9405111A (es) Nuevos derivados de (1-fenil-1-heterociclil)metanol y(1-fenil-1-heterociclil-metilamina).
DE3682225D1 (de) Carbapenemderivate, ihre herstellung und sie enthaltende pharmazeutische zusammensetzungen.
IL70253A0 (en) Nitrosourea derivatives,their preparation and pharmaceutical compositions containing them
ES461036A2 (es) Un procedimiento para la preparacion de nuevas sales de 4,5-adhidro-2-alcoxicarbonilamino-4-aril-imidazoles.
PT76335A (de) Neue basisch substituierte 4-phenyl-4,5,6,7-tetrahydro-thieno-<2,3-c>pyridine verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen
MX9203068A (es) Compuestos activirales oralmente activos.
MY111111A (en) Novel (1-phenyl-1-heterocyclyl) methanol and (1-phenyl -1-heterocyclyl) methylamine drrivatives
ES447094A1 (es) Procedimiento de preparacion de nuevos derivados de oxadia- zol.
KR890002195A (ko) 신규 2'-치환-4- 데옥시- 티아졸로[5,4-c] 리피마이신 SV 유도체
AR010808A1 (es) Uso de un compuesto para la fabricacion de un medicamento util para tratar o inhibir neutropenia y/o para acelerar la recuperacion de neutrofilos y unacomposicion farmaceutica
ES487971A1 (es) Procedimiento para la preparacion de nuevos derivados de p-cloroacetofenona oxima con actividad analgesica
MY103577A (en) New aminoacylates of glycerol acetal

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 681569

Country of ref document: ES